Abstract Number: PB1391
Meeting: ISTH 2020 Congress
Background: The prothrombotic state of the organism is observed in a number of diseases, including metabolic syndrome (MS). One of the main mechanisms of hypercoagulation in MS is an increase in platelet activity, the formation of large hyperactive platelets, and an increase in platelet aggregation (PA). Reducing pathologically elevated PA plays an important role in decreasing the prothrombotic organism status. For these purposes, direct-acting drugs are used in clinical practice. We have previously shown that regulatory lysine-containing peptides have anticoagulant and antiplatelet properties in healthy rats.
Aims: To study the influence of new proline-containing peptides with the addition of the arginine and lysine to their structure on ADP-induced PA (ADP-PA) by development of MS in rats.
Methods: The experiments were carried out on Wistar rats according to ethical principles of the Helsinki Declaration. Experimental MS was induced by feeding the rats a fat-rich high-caloric diet (HCD) during 6 weeks. MS-rats were intranasally administrated peptides KKRRPGP, RKKRPGP and KRKPGP or saline (control) for 7 days by continuation of HCD. Blood for measuring of ADP-PA was collected from v.jugular 20 h and 7 days after the last peptides injection.
Results: The our results showed that the control MS-rats had increased ADP-PA (by 43% relative to norma). RKKRPGP and KRKPGP injection to MS-rats reduced ADP-PA by 30% and 22% compared with control MS-rats, KKRRPGP didn’t change ADP-PA 20 h after peptide administration. After 7 days of peptides withdrawal the antiplatelet effect was preserved in KRKPGP, but it was not observed in KRKPGP. KKRRPGP reduces ADP-PA by 14% during this period. So, RKKRPGP administration leads to the maximum reduction in ADP-PA for a long period of time.
Conclusions: Thus lysine-containing peptides exhibit antiplatelet activity in rats with MS, reducing enhanced PA. Lysine-containing peptides can be used as promising antiplatelet drugs in prothrombotic conditions of the organism.
To cite this abstract in AMA style:Grigorjeva M, Lyapina L. Lysine-Containing Peptides as Promising Antiplatelet Drugs [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/lysine-containing-peptides-as-promising-antiplatelet-drugs/. Accessed February 25, 2024.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/lysine-containing-peptides-as-promising-antiplatelet-drugs/